Navigation Links
Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer
Date:5/20/2008

d 2003, and received at least one course of chemotherapy. The study evaluated differences in OS between patients who received treatment that was deemed responsive, intermediate-responsive or non-responsive based on ChemoFx test results.

Of the 206 patients analyzed:

-- Median OS of Assay non-responsive patients was 39.2 months

-- Median OS of Assay intermediate-responsive patients was 62.5 months

-- Median OS of Assay responsive patients was 80.4 months

When accounting for cancer stage and debulking -- the reduction of tumor size due to surgery or radiation treatment -- overall survival was significantly associated with the ChemoFx Assay and the cancer stage. In the model simulating improved survival if patients were treated with a therapy that caused a greater tumor response, median OS of patients treated with an Assay non-responsive drug could be improved from 39.2 to 62.5 months and median OS of patients treated with an Assay intermediate-responsive drug could be improved from 62.5 to 101.3 months.

"People with cancer often require additional treatment after receiving the standard of care chemotherapy. ChemoFx Assay can provide valuable information that could spare the patient from unnecessary toxicity associated with a potentially ineffective treatment," said Sean McDonald, CEO Precision Therapeutics. "The goal of ChemoFx is to empower patients and physicians with additional diagnostic information to help determine the most appropriate course of therapy for each individual patient."

This retrospective, multi-center analysis is a published abstract at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago and is available at http://www.asco.org.

About ChemoFx(R)

ChemoFx is a decision support tool that measures a specific patient's tumor response to various types, combinations and doses of chemotherapy selected by the patient's phy
'/>"/>

SOURCE Precision Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
2. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
3. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
5. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
6. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
7. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Tumor Eradication Article Published by Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)...  Decision Resources Group finds that the laparoscopic device ... will increase to a value of over $4.3 billion ... in the large direct energy device market. In particular, ... due to the advantages they offer and as new ... Decision Resources Group,s coverage of the U.S. laparoscopic device ...
(Date:12/19/2014)... KANSAS CITY, Kan. , Dec. 18, 2014 ... PETX ), a biopharmaceutical company focused on ... for companion animals, today announced positive results from ... company,s innovative drug for treating pain in dogs ... demonstrated improvements in pain assessment scores that were ...
(Date:12/17/2014)... 17, 2014 Revenue and earnings above ... research and development In the past 2013/14 fiscal ... two percent to EUR 4.287 billion (last year: EUR 4.190 ... percent to EUR 360 million. "Overall, 2013/14 was a successful ... Kaschke , President and CEO of Carl Zeiss AG. "Thanks ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2
... SAN DIEGO , April 27 ResMed Inc. (NYSE: RMD ) ... , , ... Boston on May 4, 2010 ; Jefferies Global Life Sciences Conference ... ; William Blair Growth Stock Conference at the Four Seasons in Chicago ...
... 27 Volcano Corporation (Nasdaq: VOLC ), ... guidance tools designed to enhance the diagnosis and treatment ... it has entered into a distribution agreement with AngioScore ... indications in Japan . This is the first ...
Cached Medicine Technology:ResMed Inc. to Present at Upcoming Conferences 2Volcano Announces Distribution Agreement With AngioScore for the AngioSculpt(R) PTCA Scoring Balloon Catheter in Japan 2Volcano Announces Distribution Agreement With AngioScore for the AngioSculpt(R) PTCA Scoring Balloon Catheter in Japan 3Volcano Announces Distribution Agreement With AngioScore for the AngioSculpt(R) PTCA Scoring Balloon Catheter in Japan 4
(Date:12/19/2014)... December 20, 2014 Sweetdressy.com , ... has introduced its newest selection of cheap prom dresses ... very popular in the world and clients can buy ... Meanwhile, these prom dresses feature cool cuts and delicate ... now, targeting the middle-end market. Discount shipping costs are ...
(Date:12/19/2014)... December 19, 2014 SuperCloset raises the ... Rooms. SuperCloset continues to offer indoor growers the most ... of the new SuperClone Rooms with the award winning ... turnkey indoor hydroponic grow room setup. , The SuperClone ... SuperCloset’s SuperPonic SuperCloner 50 . The ...
(Date:12/19/2014)... The print component of Vision and Hearing is distributed ... Star, with a circulation of approximately 230,433 copies and ... distributed nationally through a vast social media strategy and ... outlets. To explore the digital version of the campaign, ... an exclusive interview with Mark DeMontis , sharing his ...
(Date:12/19/2014)... drug users who also use cocaine and amphetamines have ... users, a new study finds. "We know that ... attempt and completed suicide," Didier Jutras-Aswad, a psychiatry professor ... news release. "However, there are many different profiles of ... users were actually more likely to attempt suicide." ...
(Date:12/19/2014)... Diet Doc strives to continue to ... weight loss by combining scientific fast weight ... the company understand that remaining committed to a diet ... carbohydrates and sugars from the diet can cause patients ... weight loss goals. , For this reason, Diet ...
Breaking Medicine News(10 mins):Health News:Cheap Prom Dresses Online Now at Sweetdressy.com 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2Health News:Cocaine, Amphetamines May Up Injection Drug Users' Suicide Risk 2Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 2Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 3Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 4
... , FRIDAY, Sept. 16 (HealthDay News) -- People ... clotting and inflammation have a lower five-year survival rate ... findings should be used to better treat and ensure ... said the research team from Duke University Medical Center ...
... GALVESTON, September 16, 2011 Researchers have shown for the ... cells by binding to and rendering inert protein p53, a ... of Texas Medical Branch may lead to treatments for a ... and appears in the current print issue of the ...
... has awarded $11.3 million to Case Western Reserve University ... for research on gastrointestinal cancers. The funding designates the ... in Gastrointestinal (GI) Cancers recognition extended to just ... is the primary affiliate of Case Western Reserve and ...
... WINSTON-SALEM, N.C. Sept. 16, 2011 A study ... colleagues suggests that a high intake of calcium causes ... absorbers of the mineral. "High dietary intake of ... the explanation for this observation has been elusive," said ...
... (USC) epidemiologists suggests that a high intake of calcium ... good absorbers of the mineral. "High dietary intake ... and this study suggests that these associations are likely ... professor of preventive medicine at the Keck School of ...
... highlight Pain Awareness Month in September, The ... interdisciplinary organization devoted to the field of aging is ... for seniors. Paired with its other recent research findings, ... advances in pain prevention, treatment, and management may improve care ...
Cached Medicine News:Health News:Gene Variant May Raise Death Risk After Heart Bypass 2Health News:Researchers identify potential molecular target to prevent growth of cancer cells 2Health News:National Cancer Institute establishes $11.3 million center at Case Western Reserve 2Health News:National Cancer Institute establishes $11.3 million center at Case Western Reserve 3Health News:National Cancer Institute establishes $11.3 million center at Case Western Reserve 4Health News:National Cancer Institute establishes $11.3 million center at Case Western Reserve 5Health News:National Cancer Institute establishes $11.3 million center at Case Western Reserve 6Health News:Genetics may explain why calcium increases risk for prostate cancer 2Health News:Genetics may predict why calcium increases risk for prostate cancer 2Health News:GSA sets focus on optimizing older adults' pain care 2
... super-light polypropylene mesh which offers an excellent ... considerably. Optilene Mesh LP is the alternative ... procedures. It perfectly conforms,to anatomical structures. Due ... adapts to the movements of the patient ...
... LP is a lightweight polypropylene mesh ... considerably reduced,foreign body reaction. The softer, ... It perfectly conforms to,anatomical structures. Due ... LP adapts to the movements of ...
... The Celsius Control System ... that can safely,and rapidly lower ... chosen target temperature and,rewarm patients ... Control System consists of an ...
... pump" coronary artery surgery is the latest ... is being embraced world-wide by increasing numbers ... subtle but reduced mortality, stroke, and bleeding ... benefits. A cardiac stabilizer is mandatory for ...
Medicine Products: